| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2100486 | Best Practice & Research Clinical Haematology | 2010 | 6 Pages |
Abstract
FLT3 inhibition has been a goal of acute myeloid leukemia (AML) therapy since FLT3 mutations were discovered to have a role in AML. Several FLT3 inhibitors have been developed in the last several years, beginning with less potent, less selective agents. The newer FLT3 inhibitors appear to be more potent in vivo and have shown more promise than the older agents in monotherapy trials.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Mark J. Levis,